Jackson Laboratory

The Jackson Laboratory and LG AI Research partner to pioneer biomedical advancements

Retrieved on: 
Monday, March 11, 2024
Research, Genomics, Health, Organization, FACMG, LG Corporation, LG, Data science, Data analysis, Disease, Partnership, Biomedical Research, Genetics, Patient, Biomarker, Mouse, Artificial intelligence, Cancer, Professional corporation, Human, Oncology, Pathology, Jackson Laboratory, Therapy, Genetic distance, Genetic engineering, JAX, Medical device

BAR HARBOR, Maine, March 11, 2024 /PRNewswire/ -- What can happen when prominent institutions in technology and research form a partnership to accelerate the implementation of artificial intelligence (AI) to enhance biomedical research and clinical care? A recent agreement in the field carries with it lofty aspirations.

Key Points: 
  • The Jackson Laboratory (JAX) and LG AI Research signed a partnership agreement creating an alliance between JAX's longstanding expertise in biomedical research and data analysis and LG's AI research and product development prowess.
  • "LG AI Research shares our vision to maximize the value of AI and the potential to transform human health.
  • In the past two years, LG AI Research has developed multiple AI products for biomedical applications, including EXAONE Discovery, a generative AI platform for developing new drugs and new medical materials.
  • "LG AI Research has been conducting research and development to apply AI to various industries and will continue to actively pursue research and development to achieve meaningful results with AI technology, especially in the biofield, which is the future growth engine of the LG Group," said Kyunghoon Bae, Ph.D., president of LG AI Research.

Associate Professor Ron Korstanje, Ph.D., of The Jackson Laboratory named Evnin Family Chair

Retrieved on: 
Friday, March 1, 2024
SSP, Ageing, Metabolism, Research, Alzheimer's disease, Zebrafish, Jackson Laboratory, University, Mentorship, Genetics, Organization, Associate, Family, Gene, JAX, Disease, Genomics, Life, Publication, Biology, Mouse, Student, Pharmaceutical industry

BAR HARBOR, Maine, March 1, 2024 /PRNewswire/ -- Associate Professor Ron Korstanje, Ph.D., has been named the Evnin Family Chair at The Jackson Laboratory. An expert in the genetics of kidney function and disease, Korstanje's appointment marks a new chapter in his 20 years of service to JAX's mission. 

Key Points: 
  • BAR HARBOR, Maine, March 1, 2024 /PRNewswire/ -- Associate Professor Ron Korstanje, Ph.D., has been named the Evnin Family Chair at The Jackson Laboratory.
  • "His appointment as the Evnin Family Chair bolsters our commitment to understanding the most complex health challenges of our time.
  • I'm grateful to him, and to the Evnin family for their support in helping us recruit and retain top scientists."
  • After returning to JAX in 2007 as a research scientist in Paigen's laboratory, he advanced to the rank of associate professor in 2019.

Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS

Retrieved on: 
Tuesday, January 16, 2024
Pathology, Patient, Target, Research, ALS, Dew point, ALS Association, C9orf72, Biotechnology, Science, Repeat, Jackson Laboratory, Mutation, Epistasis, Disease, Therapy, Neurodegenerative disease, Pharmaceutical industry

Challenges to develop effective therapeutics for ALS stem, in part, from the diverse, and poorly understood genetic background of the patients.

Key Points: 
  • Challenges to develop effective therapeutics for ALS stem, in part, from the diverse, and poorly understood genetic background of the patients.
  • Dewpoint leverages an aberration that occurs in ~97% of all ALS patients – independent of genetic background – to drive the discovery and development of a new, and potentially more effective class of therapeutics.
  • “Receiving the Target ALS grant is a tremendous honor and a significant validation for Dewpoint’s novel, therapeutic approach to target condensatopathies,” said Ameet Nathwani, CEO of Dewpoint Therapeutics.
  • Dr. Amy Easton, Sr. Director of Scientific Programs at Target ALS said "Target ALS is excited to fund the generation of in vivo target validation data to support development of Dewpoint Therapeutics’ clinical candidate for ALS.

Charles Lee of The Jackson Laboratory inducted as a fellow of The Korean Academy of Science and Technology

Retrieved on: 
Thursday, December 14, 2023
Genetic distance, AAAS, Genetics, Research, Jackson Laboratory, FACMG, Disease, KAST, Genomics, Ho-Am Prize in Science, HUGO, JAX, Faculty, Human Genome Organisation, Health, DSM-IV codes, Genome, Harvard Medical School, Natural science, Brigham and Women's Hospital, Biology, AACR, Hospital, Lee, Pharmaceutical industry, Medicine

FARMINGTON, Conn., Dec. 14, 2023 /PRNewswire/ -- The Korean Academy of Science and Technology (KAST), the highest institution of its kind in South Korea, announced Charles Lee, Ph.D., FACMG , as a newly inducted fellow of the Academy.

Key Points: 
  • FARMINGTON, Conn., Dec. 14, 2023 /PRNewswire/ -- The Korean Academy of Science and Technology (KAST), the highest institution of its kind in South Korea, announced Charles Lee, Ph.D., FACMG , as a newly inducted fellow of the Academy.
  • Lee is the scientific director and professor at The Jackson Laboratory for Genomic Medicine, and is the Robert Alvine Family Endowed Chair.
  • "I am profoundly honored to join so many inspirational scientists and colleagues who are members of the Korean Academy of Science and Technology, and am deeply grateful for this tremendous opportunity," says Lee.
  • Dr. Lee is also responsible for the scientific direction and coordination of The Jackson Laboratory (JAX) for Genomic Medicine.

Maine Hospital Association Has Partnered with Husson University for Workforce Development

Retrieved on: 
Tuesday, October 24, 2023
Science, Opus College of Business, Humanities, Education, Health, Master of Business Administration, L.L.Bean, Workforce, Organization, Bangor Savings Bank, MBA, College, Growth, Husson University, Business administration, Student, Partnership, Business, MHA, Jackson Laboratory, Insurance, Communication, Nursing, Management

BANGOR, MAINE, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Maine Hospital Association members and employees can now take courses and work toward certificates and degrees at Husson University at a discounted rate thanks to a recent agreement between the organization and the school.

Key Points: 
  • BANGOR, MAINE, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Maine Hospital Association members and employees can now take courses and work toward certificates and degrees at Husson University at a discounted rate thanks to a recent agreement between the organization and the school.
  • The partnership allows Maine Hospital Association members and employees a tuition discount on courses toward undergraduate degrees, masters degrees and certificates.
  • We are so thrilled to partner with the Maine Hospital Association to support higher education among their members,” said Dr. Marie Hansen, dean of the College of Business.
  • Together with Husson, we're fostering the future of healthcare in Maine,” said Steven Michaud, president of the Maine Hospital Association.

Announcing the Digital In Vivo Alliance (DIVA), a precompetitive consortium to develop, validate and promote the use of AI-enabled digital biomarkers in preclinical in vivo research.

Retrieved on: 
Thursday, October 19, 2023
Digital, Biomarker, DVM, Calico (company), Respiratory disease, Doctor of Philosophy, Research, Multimedia, Public sector, BioMarin Pharmaceutical, Novartis, Machine learning, DIVA, Algorithm, AbbVie, Jackson Laboratory, AI, Epilepsy, Patient, Dermatitis, SAN, Medical imaging, Vaccine

DIVA has the mission to collaboratively advance digital biomarkers for preclinical in vivo research through their development, validation, adoption, and regulatory acceptance.

Key Points: 
  • DIVA has the mission to collaboratively advance digital biomarkers for preclinical in vivo research through their development, validation, adoption, and regulatory acceptance.
  • Digital In Vivo Alliance members work together non-competitively, for the purpose of exploring preclinical applications of AI-enabled digital biomarkers from home cage-compatible technologies.
  • This collaborative approach serves to accelerate the understanding and integration of digital biomarkers in preclinical models, fortifying our shared vision of enabling novel therapies through the adoption of digital biomarkers in AI-enhanced in vivo research.
  • Inquiries about DIVA and the discovery, development, and adoption of digital biomarkers can be directed to the Digital In Vivo Alliance using the contact information below or at DIVA.bio .

Zylö’s ‘Powered By Z-pod’ Technology Featured in Peer-Reviewed Paper Published in Experimental Dermatology

Retrieved on: 
Wednesday, September 27, 2023
Mouse, Dermatology, Jackson Laboratory, Clinical and Experimental Dermatology, Dermis, AEA, Pharmaceutical industry

GREENVILLE, SC, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The Z-pod® topical delivery platform was used in various in vivo studies that were highlighted in a peer-reviewed paper just published online by Experimental Dermatology titled, “Nano-encapsulated anandamide (AEA) reduces inflammatory cytokines in vitro and lesion severity in a murine model of cutaneous lupus erythematosus [CLE].”

Key Points: 
  • His colleagues at George Washington University (GWU) and AECOM wrote the paper, designed the studies, and performed some of the studies.
  • Approximately 500,000 people in the U.S. suffer from cutaneous lupus erythematosus (CLE), with a significant impact on quality of life.
  • Moreover, the technology enables the use of a novel active ingredient that otherwise would not be an effective tool in managing this disease.
  • The principal investigator of the grant-work is Zylö’s A. Draganski, and the primary collaborator is Dr. Werth.

The Jackson Laboratory names Meghan Finn Vice President and Chief Communications Officer

Retrieved on: 
Wednesday, September 20, 2023
Communication, Advertising, Society, Genetics, National Multiple Sclerosis Society, Biomedical Research, Research, Genomics, Breast, Iona University, Jackson Laboratory, Finn, BCRF, Fellow of the Academy of Medical Sciences, Council, JAX, Breast Cancer Research Foundation, Growth, Health, Breast cancer, Management

FARMINGTON, Conn., Sept. 20, 2023 /PRNewswire/ -- Meghan Finn has joined The Jackson Laboratory, an independent, nonprofit biomedical research institution, as Vice President and Chief Communications Officer.

Key Points: 
  • FARMINGTON, Conn., Sept. 20, 2023 /PRNewswire/ -- Meghan Finn has joined The Jackson Laboratory, an independent, nonprofit biomedical research institution, as Vice President and Chief Communications Officer.
  • "We are thrilled to welcome Meghan Finn as JAX's newly appointed vice president and chief communications officer," said Lon Cardon , Ph.D., FMedSci, president and CEO.
  • Prior to BCRF, Meghan was employed at the National Multiple Sclerosis Society, where she held a variety of positions, most recently vice president of brand and communications.
  • A member of Chief and the Forbes Nonprofit Council, Meghan also serves on the President's Council of Northwell Health Northern Westchester Hospital.

Clinical whole genome sequencing test developed at The Jackson Laboratory

Retrieved on: 
Friday, September 15, 2023
Hospice and palliative medicine, DNA, CAP, Genome, Genetic distance, DSM-IV codes, APML, Jackson Laboratory, CLIA, Protein, Patient, JAX, Education minister, Diagnosis, Disease, Antibiotics, Vaccine

A decade ago, sequencing centers began offering clinical whole exome sequencing, but these only cover the portion of the genome that codes for proteins – approximately 1.5 percent of the entire genome.

Key Points: 
  • A decade ago, sequencing centers began offering clinical whole exome sequencing, but these only cover the portion of the genome that codes for proteins – approximately 1.5 percent of the entire genome.
  • To improve the diagnostic power of sequencing and identify the genetic basis of disease, the Advanced Precision Medicine Laboratory (APML) at The Jackson Laboratory for Genomic Medicine (JAX) in Farmington, Connecticut, is offering a fully validated, clinical whole genome sequencing test.
  • The APML is CLIA certified and CAP accredited and the JAX Genome test is the only clinical whole genome sequencing test currently offered in Connecticut.
  • The JAX Genome test includes DNA extraction from whole blood, sequencing of the genome, and variant analysis and interpretation.

Actio Biosciences Announces $55 Million Series A Financing to Advance Precision Medicine Approach for Rare and Common Diseases

Retrieved on: 
Tuesday, September 12, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, EcoRI, Partnership, Probability, Therapy, Vocal cord paresis, Atlas, Biomedical Research, Bone, Jackson Laboratory, Translation, Chemistry, Muscle weakness, Patient, Medicine, JAX, Drug discovery, Biology, Rare, Gene, TRPV4, Disease, Pharmaceutical industry, Vaccine, Management, Pronuntiatio

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced the completion of a $55 million Series A financing.

Key Points: 
  • Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced the completion of a $55 million Series A financing.
  • The financing was led by Canaan and DROIA Ventures, with participation from existing investors Deerfield Management and EcoR1, as well as new investor Euclidean Capital.
  • The company’s platform comprises a vast proprietary target database, called the Rare Disease Target Atlas, and unparalleled expertise in bioinformatics, biology and chemistry.
  • Actio’s pipeline is led by a program targeting TRPV4, an ion channel target identified as high-value through the company’s platform.